Company intelligence / Profile preview

Iceland Spar Biotechnology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Iceland Spar Biotechnology is a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, including obesity and type 2 diabetes. The company leverages advanced structure-based drug design and computational chemistry to develop next-generation incretin mimetics and multi-receptor agonists. Their research primarily targets the GLP-1, GIP, and glucagon pathways to create more effective and tolerable treatments for metabolic syndrome. Iceland Spar aims to address significant unmet medical needs in the global healthcare market through its specialized focus on metabolic health and peptide engineering.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Iceland Spar Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iceland Spar Biotechnology.

Explore the full profile